Fluoropyrimidine combinations showed no clear difference in overall survival compared with fluoropyrimidine alone (low certainty).
5‐FU/cisplatin/anthracycline combinations may leads to lower overall survival compared with 5‐FU/anthracycline combinations (without cisplatin) (low certainty).
Irinotecan probably leads to lower overall survival compared with non‐irinotecan‐containing regimens (moderate certainty).
Docetaxel leads to lower overall survival compared with non‐docetaxel‐containing regimens (high certainty).
Capecitabine showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (moderate certainty).
Oxaliplatin may leads to lower overall Survival compared with the same regimen including cisplatin (low certainty).
It is very uncertain whether taxane‐platinum‐fluoropyrimidine combinations changes overall survival compared with taxane‐platinum (without fluoropyrimidine) (very low certainty).
S‐1 showed no clear difference in overall Survival compared with 5‐FU‐containing regimens (high certainty).
5‐FU/cisplatin/anthracycline combinations probably leads to lower overall survival compared with 5‐FU/cisplatin combinations (without anthracyclines) (moderate certainty).
Irinotecan‐based regimens showed no clear difference in overall survival compared with irinotecan (low certainty).
Irinotecan + oxaliplatin probably leads to lower overall survival compared with irinotecan (moderate certainty).
The intervention showed no clear difference in overall survival (high certainty).
The intervention leads to lower overall survival (high certainty).
Non‐platinum single‐agent may leads to lower overall survival (OS) compared with non‐platinum combination treatment (low certainty).
Non‐platinum therapies probably leads to lower overall survival compared with platinum combination (moderate certainty).
The intervention leads to lower overall survival1 (high certainty).
The intervention showed no clear difference in overall survival (moderate certainty).
Sunitinib showed no clear difference in overall survival (absolute effect size estimates based on survival… compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).
Sunitinib probably leads to higher overall survival (absolute effect size estimates based on survival… compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (moderate certainty).